Market Overview

Conceptus(R) to Hold First Quarter Financial Results Conference Call on April 26, 2012

MOUNTAIN VIEW, Calif., April 5, 2012 (GLOBE NEWSWIRE) -- Conceptus, Inc. (Nasdaq: CPTS), developer of the Essure® procedure, the leading non-surgical permanent birth control method, today announced that the Company will release 2012 first quarter financial results on Thursday, April 26, 2012, after the close of market. Management will host an investment community conference call beginning at 4:30 p.m. Eastern time on April 26, 2012, to discuss the results and answer questions.

Conference call dial-in information is as follows:

  • U.S. callers: (888) 803-8296
  • International callers: (706) 634-1250

Individuals interested in listening to the live conference call via the Internet may do so by logging on to the Company's website, www.conceptus.com.

A telephone replay will be available from 6:30 p.m. Eastern time on April 26, 2012, through 11:59 p.m. Eastern time on April 30, 2012.  Replay dial-in information is as follows:

  • U.S. callers: (855) 859-2056
  • International callers: (404) 537-3406
  • Conference ID number (U.S. and international): 69218699
  • The replay will also be available at www.conceptus.com

About the Essure® Procedure

The Essure procedure, FDA approved since 2002, is the first permanent birth control method that can be performed in the comfort of a physician's office in less than 10 minutes (average hysteroscopic time) without hormones, cutting, burning or the risks associated with general anesthesia or tubal ligation. Soft, flexible inserts are placed in a woman's fallopian tubes through the cervix without incisions. Over the next three months, the body forms a natural barrier around and through the inserts to prevent sperm from reaching the egg.  Three months after the Essure procedure, a doctor is able to perform an Essure Confirmation Test to confirm that the inserts are properly placed and that the fallopian tubes are fully blocked, allowing the patient to rely upon Essure for permanent birth control.

The Essure procedure is 99.95% effective based on one year of follow up with zero pregnancies reported in clinical trials, making it the most effective form of permanent birth control on the market. The procedure is covered by most insurance plans, and when it is performed in a doctor's office the cost to the patient may be as low as a simple co-pay. Essure has been proven and trusted by physicians since 2002, with more than 600,000 women worldwide having undergone the Essure procedure.

About Conceptus®, Inc.

Conceptus, Inc. is a leader in the design, development and marketing of innovative solutions in women's healthcare. The Company manufactures and markets the Essure procedure. The Essure procedure is available in the United States, Europe, Australia, New Zealand, Canada, Mexico, Central and South America and the Middle East. 

The Conceptus, Inc. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=7961

Please visit www.essure.com for more information on the Essure procedure. Patients may call the Essure Information Center at 1-877-ESSURE-1 with questions or to find a physician in their area.

© 2012 Conceptus, Inc.—All rights reserved.

CONTACT: Investor Relations and Public Relations Contact: Cindy Klimstra (650) 962-4032 cindy_klimstra@conceptus.com

Conceptus, Inc. Logo

 

Around the Web, We're Loving...

Partner Network

Get Benzinga's Newsletters

Benzinga Professional